Light at night, chronodisruption, melatonin suppression, and cancer risk: a review - PubMed (original) (raw)

Review

Light at night, chronodisruption, melatonin suppression, and cancer risk: a review

Russel J Reiter et al. Crit Rev Oncog. 2007 Dec.

Abstract

Light exposure during the night is becoming progressively more common throughout the world, particularly in areas where electricity is commonly used. Also, the availability of artificial light has allowed humans to work or recreate throughout the 24-hour day. Based on photographs taken of the Earth from outer space, it is also apparent that true darkness is disappearing. For years it was assumed that polluting the daily dark period with light was inconsequential in terms of animal/human physiology. That assumption, however, has proven incorrect. Light at night has two major physiological actions, i.e., it disrupts circadian rhythms and suppresses the production of melatonin by the pineal gland. Moreover, both these changes are light intensity and wavelength dependent. Both human epidemiological and experimental studies on animals have documented that a potential negative consequence of chronodisruption and nocturnal melatonin inhibition is cancer initiation and growth. In epidemiological studies, the frequency of each of the following cancers has been reportedly increased in individuals who routinely work at night or whose circadian rhythms are disrupted for other reasons (e.g., due to jet lag): breast, prostate, endometrial, and colorectal. Likewise, in experimental animals, cancer growth is exaggerated when the animals are repeatedly phase advanced (as occurs during easterly flights) or exposed to light at night. A variety of mechanisms have been examined to explain how the suppression of melatonin exaggerates cancer risk. Mechanistically, how chronodisruption (without a consideration of melatonin suppression) would enhance cancer frequency is less clear. In addition to cancer, there may be other diseases that result from the chronic suppression of melatonin by light at night.

PubMed Disclaimer

Cited by

Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.
Hardeland R. Hardeland R. Aging Dis. 2012 Apr;3(2):194-225. Epub 2011 Feb 10. Aging Dis. 2012. PMID: 22724080 Free PMC article.
Melatonin: an inhibitor of breast cancer.
Hill SM, Belancio VP, Dauchy RT, Xiang S, Brimer S, Mao L, Hauch A, Lundberg PW, Summers W, Yuan L, Frasch T, Blask DE. Hill SM, et al. Endocr Relat Cancer. 2015 Jun;22(3):R183-204. doi: 10.1530/ERC-15-0030. Epub 2015 Apr 15. Endocr Relat Cancer. 2015. PMID: 25876649 Free PMC article. Review.
Sleep Traits, Night Shift Work and Lung Cancer Risk among Women: Results from a Population-Based Case-Control Study in France (The WELCA Study).
Cordina-Duverger E, Uchai S, Tvardik N, Billmann R, Martin D, Trédaniel J, Wislez M, Blons H, Laurent-Puig P, Antoine M, Guénel P, Radoï L, Welca Study Group. Cordina-Duverger E, et al. Int J Environ Res Public Health. 2022 Dec 4;19(23):16246. doi: 10.3390/ijerph192316246. Int J Environ Res Public Health. 2022. PMID: 36498320 Free PMC article.
The effects of screen light filtering software on cognitive performance and sleep among night workers.
Kazemi R, Alighanbari N, Zamanian Z. Kazemi R, et al. Health Promot Perspect. 2019 Aug 6;9(3):233-240. doi: 10.15171/hpp.2019.32. eCollection 2019. Health Promot Perspect. 2019. PMID: 31508344 Free PMC article.
The Effect of Light Exposure at Night (LAN) on Carcinogenesis via Decreased Nocturnal Melatonin Synthesis.
Giudice A, Crispo A, Grimaldi M, Polo A, Bimonte S, Capunzo M, Amore A, D'Arena G, Cerino P, Budillon A, Botti G, Costantini S, Montella M. Giudice A, et al. Molecules. 2018 May 29;23(6):1308. doi: 10.3390/molecules23061308. Molecules. 2018. PMID: 29844288 Free PMC article. Review.

Light at night, chronodisruption, melatonin suppression, and cancer risk: a review - PubMed (original) (raw)